EP3291811
THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC)
:
EP einkaleyfi: Þýðing ekki lögð inn:
2.5.2016:
7.8.2019:
16719430.7
:
1.5.2036
:
THE USE OF SGC STIMULATORS, SGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF DIGITAL ULCERS (DU) CONCOMITANT TO SYSTEMIC SCLEROSIS (SSC)
2.5.2016
7.8.2019
:
Bayer Pharma Aktiengesellschaft:
Müllerstrasse 178, 13353, Berlin, DE
:
HIRTH-DIETRICH, Claudia:
Wuppertal, DE
:
SANDNER, Peter:
Wuppertal, DE
:
STASCH, Johannes-Peter:
Grottaferrata, IT
:
HAHN, Michael:
Langenfeld, DE
:
FOLLMANN, Markus:
Köln, DE
:
VAKALOPOULOS, Alexandros:
Hilden, DE
:
15166516:
6.5.2015:
EP
:
EP2016059734:
2.5.2016
:
A61K 31/426, A61K 31/427, A61K 31/4439, A61K 31/506, A61K 31/519, A61K 31/5377, A61K 31/635, A61K 45/06, A61P 17/02, A61K 31/197, A61K 31/53